KPRX (Kiora Pharmaceuticals) Short Interest


KPRX Kiora Pharmaceuticals Inc KPRX
33 GF Score
Price $2.55
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

KPRX vs BRTX, INTS, ERNA: Short Interest Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiora Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Short Interest falls into.


KPRX
33GF Score
Kiora Pharmaceuticals Inc KPRX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
33GF Score

Get the complete analysis for KPRX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.55
Price